56926-48-8

Upstream product

• 56926-46-6 2-Benzyloxy-5-phenylbenzoesaeure 
• 917-54-4 methyllithium 
• 14031-80-2 2-hydroxy-5-phenylacetophenone 
• 100-39-0 benzyl bromide 
• 148-86-7 4-acetoxybiphenyl 
• 56926-44-4 Ethyl-2-benzyloxy-5-phenylbenzoat 
• 17504-14-2 ethyl 4-hydroxy-[1,1'-biphenyl]-3-carboxylate 
• 92-03-5 2-bromo-4-phenylphenol 
• 92-69-3 4-Phenylphenol 
• 75-36-5 acetyl chloride 
• 114250-18-9 2-bromo-1-(phenylmethoxy)-4-phenylbenzene 

Downstream Products

• 114250-24-7 methyl β-oxo-4-(phenylmethoxy)<1,1'-biphenyl>-3-propanoate 
• 56926-50-2 Ethyl-2,4-dioxo-4-(2'-benzyloxy-5'-phenylphenyl)-butyrat 
• 114250-10-1 3,4-dihydroxy-6-phenyl-2H-1-benzopyran-2-one 
• 114250-31-6 methyl β-oxo-4-(phenylmethoxy)-α-<<(phenylmethoxy)carbonyl>oxy><1,1'-biphenyl>-3-propanoate 

Relevant academic research and scientific papers

WB4101-related compounds: New, subtype-selective α1- adrenoreceptor antagonists (or inverse agonists?)

Our previous structure-affinity relationship study had considered the enantiomers of the naphthodioxane, tetrahydronaphthodioxane, and 2-methoxy-1-naphthoxy analogues (compounds 1, 3, and 2, respectively) of 2-(2,6-dimethoxyphenoxyethylaminomethyl)-1,4-be

Synthetic aci-Reductones: 3,4-Dihydroxy-2H-1-benzopyran-2-ones and Their cis- and trans-4a,5,6,7,8,8a-Hexahydro Diastereomers. Antiaggregatory, Antilipidemic, and Redox Properties Compared to Those of the 4-Substituted 2-Hydroxytetronic Acids

Synthetic procedures for the elaboration of aci-reductones belonging to the 6- or 7-mono- or bis-substituted-3,4-dihydroxy-2H-1-benzopyran-2-ones (6 - 10) and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers (11, 12) are described.Hexahydrobenzo

Synthesis of ethyl 6-substituted-chroman- and -chromone-2-carboxylates. A comparative structure-activity study employing the 6-phenyl and phenoxy analogs in the triton hyperlipidemic rat model.

To explore the effect of lipophilicity on antilipidemic activity in the Triton WR-1339 induced hyperlipidemic rat model we synthesized the 6-cyclohexyl, phenyl, and phenoxy analogs of ethyl chroman-2-carboxylate. Results obtained were analyzed in light of the biological activity observed for the 6-chloro-substituted and unsubstituted chromans, the 6-chlorochroman-4-one ester, and the 6-chloro-, phenyl-, and phenoxychromone esters. The suggestion is made that chromones likely exert their antilipidemic effects by a somewhat different set of mechanisms than do the chromans and clofibrate. Whereas the 6-chlorochromanone ester is inactive, the 6-chlorochromone ester is active in both normal and hyperlipidemic Sprague-Dawley rats. The major differential effect was observed for ethyl 6-cyclohexylchroman-2-carboxylate which did not lower cholesterol levels but returned triglyceride levels to normal in hyperlipidemic rats.